|Medtronic Outlines Future Growth Opportunities at Investor Conference|
MINNEAPOLIS -- Jun. 5, 2014 -- Medtronic, Inc. (NYSE: MDT) shared during its Investor Conference today in New York City an overview of the state of its business and strategies for future growth opportunities. Chairman and CEO Omar Ishrak emphasized the opportunity that exists to address universal healthcare needs: improving clinical outcomes, expanding access, and optimizing cost and efficiency. He also emphasized the company's integrated health solutions offerings and focus on improving operational execution to deliver consistent results.
"We are uniquely positioned to deliver long-term value in healthcare by expanding our market-leading franchises through three differentiated strategies - therapy innovation, globalization and economic value - to create long-term value in healthcare," said Ishrak. "Furthermore, reliable performance with disciplined capital allocation will create long-term shareholder value."
Through its therapy innovation strategy, the company will invest approximately $8.5 billion in research and development over the next five years to drive growth through a pipeline of more than 200 projects. The globalization strategy is focused first on expanding access to current therapies, including through private and public partnerships, as well as channel optimization. In the shift to value-based healthcare, Medtronic emphasized the importance of accountability for outcomes in healthcare over a fee-for-services model of healthcare delivery.
The management team across Medtronic's business groups highlighted the company's strong cadence of product launches, geographic expansion and focus on economic value. Highlights from the business groups include:
"We are focused on being the leading medical technology partner of choice for hospitals, health systems, payers and governments," said Ishrak.
An archived webcast of Medtronic's 2014 Investor Conference will be available via the company's website at www.medtronic.com later today.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
- end -